Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon
Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.
Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.